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ABSTRACT
Relationship Between Total Body Mass, Fat-Free Mass, Fat Mass,
and Bone Mineral Density of the Hip in Middle-Age Women:
The Roles of Diet, Physical Activity, and Menopause
Elizabeth R. Fosson
Department of Exercise Sciences, BYU
Master of Science
Objective: This study was conducted to investigate the relationship between hip bone mineral
density (BMD), fat-free mass (FFM), fat mass (FM), and total body mass (TBM) and the extent
to which these relationships were modified by various confounding factors. The cross-sectional
analysis included 262 healthy females (mean age 41.6±3.0 years). Methods: BMD of the hip and
body composition were assessed by the Hologic 4500W dual energy x-ray absorptiometry
(DXA) system. Total and intensity of physical activity (PA) were objectively measured using an
Actigraph accelerometer. Dietary calcium and vitamin D from food and beverages, as well as
from supplements, were measured separately using the Block food frequency questionnaire.
Menopause status and prescription bone drug use were measured by a questionnaire. Results:
The relationship between FFM and hip BMD was strong and robust (F=24.5, P<0.0001). Using
the pooled standard deviation revealed a large effect size of 1.2 when comparing hip BMD of
women with low FFM and high FFM. Potentially confounding variables, considered individually
and collectively, did not change this relationship. The association between FM and hip BMD was
also substantial (F=9.9, P<0.0001) and remained significant when controlling for all potentially
confounding variables, except differences in FFM. The relationship between TBM and hip BMD
was also strong and dose-response (F=21.5, P<0.0001) and remained significant, except when
differences in FFM were controlled. Conclusion: The relationships between body mass (total,
fat, and fat-free) and BMD of the hip in middle-age women are strong and significant. The
associations are not influenced by differences in age, height, menopause status, calcium or
vitamin D intake, volume or intensity of PA, or the use of bone enhancing prescription drugs.
The findings suggest that women with low body mass, particularly low FFM, tend to have low
hip BMD and there is little that can be done to change this association.

Keywords: osteoporosis, body composition, cross-sectional, DXA, calcium, vitamin D,
premenopausal
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INTRODUCTION
Osteoporosis is a skeletal disease characterized by extremely low bone mineral density
accompanied by increased fracture risk (1). In osteoporosis, bone tissue is lost which makes
bones porous, fragile, and brittle and much more likely to fracture (2). Osteopenia is a less severe
type of bone loss where individuals have lower bone mineral density than normal, but do not
have osteoporosis (3). Osteoporosis influences millions of people each year and rates continue to
increase, causing an economic burden of nearly $20 billion (4). The incidence of fractures related
to osteoporosis is at an all-time high throughout the world with current osteoporosis estimates at
roughly 200 million, including approximately 44 million estimated cases in the United States
alone (5).
Some studies show that bone mineral density is the single greatest predictor of future
fracture risk, suggesting that maximizing bone density is a key for osteoporosis prevention (6).
Bone mineral density (BMD) increases in response to stresses placed on the bones (7). Body
mass is one such stressor that seems to have a positive influence on BMD, according to the
literature (8, 9). In short, excess body mass puts increased stress on bones which tends to
increase their strength. Those who have a low body mass tend to have lower BMD, particularly
in women (10).
Individuals with higher risk of developing osteoporosis and osteopenia include those who
have low body mass, less fat-free mass (FFM), the elderly, and postmenopausal women (11).
Among these characteristics, body composition plays a key role in BMD status, with FFM being
the most predictive of BMD levels (12-14). Recent research shows a strong and robust
relationship between FFM and BMD and a less clear relationship between fat mass (FM) and
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BMD. Apparently, an elevated body mass may not be as protective against osteoporosis as
previously proposed, if that body mass is comprised of a large percentage of body fat (15-17).
Other factors that are predictive of BMD include age (18-21), physical activity (22-26),
calcium and vitamin D intake (27-32), menopause status (33, 34), and the use of bone enhancing
prescription drugs (35-38). The extent to which these factors influence the strong link between
FFM and BMD has not been studied. Yet, these are critical questions. If individuals have low
body mass, or particularly low FFM, are they destined to have low BMD? Are the strong
associations between total body mass and FFM, as they relate to BMD, unchangeable? Can
calcium and vitamin D intake, physical activity levels, menopause status, or other factors
influence the association between FFM and BMD? To date, research has neglected to address
these important questions.
The objective of the present study was to investigate the relationships between total body
mass, FFM, fat-free mass minus bone mineral content (FFM-BMC), FM, and BMD of the hip
and the extent to which these associations were influenced by the following potentially
confounding variables: age, height, objectively measured total, vigorous, and moderate physical
activity, calcium and vitamin D intake from food, beverages, and supplements, menopause
status, and bone enhancing prescription drug use, studied individually and collectively. In short,
if any of these variables was found to significantly influence the relationship between body mass
and BMD, then osteoporosis prevention efforts could focus on that factor.

METHODS
Subjects
A cross-sectional design was employed and recruitment of participants was accomplished
through newspaper advertisements in approximately 20 different cities throughout the Mountain
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West region of the US. The final sample for this study included 262 women who varied in their
menopause status, and had a mean age of 41.6±3.0 years. Subjects were free from chronic
diseases as assessed by the Physical Activity Readiness Questionnaire (PAR-Q). Sample
characteristics included the following: non-smokers, 90% non-Hispanic White, 80% married,
and 37% had some college education. The study was approved by the Institutional Review Board
at Brigham Young University. All subjects signed an informed consent document before
participating in the study.
Procedures
Measurements were taken at the university Human Performance Research Center by
trained research assistants during two separate appointments spaced by one week. Participants
were asked to fast three hours prior to their arrival for the first appointment, however water
intake was encouraged. Each participant changed into a form-fitting, one-piece lab-issued
swimsuit to wear for the weighing and the DXA scan, and was instructed to eliminate any body
waste before measurements were taken. Using a calibrated electronic scale (Tanita, Tokyo,
Japan), subjects were weighed to the nearest 0.05 kg. After this, each subject had a total body
scan using a Hologic 4500W DXA system (Hologic, Bedford, MA) to measure bone mineral
density and body composition.
Upon completion of the scan, subjects were given two questionnaires: the Block food
frequency questionnaire (Nutrition Quest, Berkeley, CA) and a questionnaire designed to assess
menopause status and bone enhancing prescription drug use. Before leaving the laboratory,
subjects were issued an Actigraph model 7164 accelerometer (Health One Technology, Fort
Walton Beach, FL) which recorded the volume and intensity of physical activity over the
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following seven days. Subjects received detailed verbal and written instructions regarding how to
properly wear and use the accelerometer.
One week later, subjects returned to the lab with their completed questionnaires and the
accelerometer. Data from the accelerometer were downloaded and checked for errors. If there
were any errors on the questionnaire or accelerometer, subjects were contacted and the
appropriate corrections were made.
Instrumentation and Measurements
In the present study, bone mineral density of the hip was the criterion variable. Various
measurements of body mass were employed as predictor variables. Age, height, total and
intensity of physical activity, dietary and supplemental intake of calcium and vitamin D,
menopause status, and the use of bone enhancing prescription drugs were studied as potential
mediating variables.
Bone Mineral Density
Bone mineral density (BMD) was measured using dual energy x-ray absorptiometry
(DXA), with a Hologic QDR 4500W bone densitometer (Hologic, Bedford, MA). This
instrument is considered a reliable and valid measurement of bone mineral density, as well as a
safe measurement tool that exposes individuals to minimal amounts of radiation (39-41).
In a cross-sectional study involving 210 postmenopausal women, the Hologic QDR 4500
was used to assess bone mineral density (42). Researchers found that precision error was only
2% for the lumbar spine, 1.8% for the femoral neck, and 1.5% for whole body bone mineral
density (42). Others have found precision error of the QDR 4500 to be less than 1% (43).
The 4500W was calibrated at the beginning of each testing day. To confirm accuracy,
laser light cross-hairs emitted by the 4500W enabled the licensed technician to consistently
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position subjects beneath the same spot of the scanning arm. Scans of the left hip were made
after ensuring that the laser cross-hairs bisected the thigh at a position directly even with the
pubic bone. To minimize the view of the lesser trochanter and femoral shaft, the subject’s left leg
was internally rotated and slightly abducted and then attached to a positioning aide.
Body Composition
The DXA screening included body composition results as an additional assessment.
Specifically, fat-free mass (FFM), fat mass (FM), and fat-free mass minus bone mineral content
(FFM-BMC) were analyzed. Total body mass included both FFM and FM. FM was the portion
of total body mass that only included fat tissue mass. BMD was a measure of BMC per unit of
volume of bone. FFM was defined as all components that give mass to the body, excluding fat
tissue, including skeletal and muscle tissue, bone, and water. Because FFM includes bone mass,
and because BMD is partly a function of bone mass, it follows that FFM and BMD tend to be
correlated. To remove the direct effect of bone mass on FFM in the present study, a new variable
was created, FFM-BMC (FFM minus bone mineral content). In short, the variable FFM-BMC
was comprised of all components of body mass minus fat mass and bone mass.
Body composition analysis performed by DXA is considered reliable and valid (44-46).
Test-retest reliability of the instrument when measured on 100 subjects from the present study
resulted in a high intraclass correlation (r=0.999) (47). When the DXA results were compared to
Bod Pod results for the same 100 subjects, a Pearson correlation of 0.94 (P<0.001) and an
intraclass correlation of 0.97 (P<0.001) were found (48).
Total and Intensity of Physical Activity
For seven consecutive days, each subject wore an Actigraph model 7164 accelerometer
(Health One Technology, Fort Walton Beach, FL) to assess total and intensity of physical

6
activity. Actigraph accelerometers are considered a reliable and valid instrument to measure
physical activity (49-55).
Correctly wearing the accelerometer consisted of placing it in a small, nylon pouch
attached to a waist belt that was worn at the level of the umbilicus directly over the left hip.
Participants were instructed to wear the accelerometer continuously during each day and night of
the measurement period except when they were bathing or engaging in other water-related
activities. Failure to wear the accelerometer as instructed resulted in the subject having to wear it
again on the day(s) of the week they did not wear it properly. A failed day was defined as not
wearing the accelerometer for two or more hours. For the analysis, a day of wear was defined as
activity counts derived between the hours of 7 am to 11 pm. Mean wear time during that time (a
15 hr period) was 13.9 hrs (93% wear time compliance) over the seven days.
The 2007 American College of Sports Medicine (ACSM) and American Heart
Association (AHA) physical activity recommendations indicate that accumulating 10-minute
bouts of moderate intensity aerobic activity totaling at least 30 minutes daily is sufficient activity
to improve health (56). Therefore, analysis time was divided into 10-minute bouts, or epochs,
which resulted in a total of 144 epochs for each day, and 1008 epochs for the seven day period.
Total physical activity (tPA) was calculated as the sum of all physical activity counts over the
seven consecutive days. Intensity of physical activity (iPA) was calculated by analyzing the
physical activity counts obtained during each 10-minute bout, and categories were created based
on these totals used in other investigations (57-59). Sedentary activity included 10-minute bouts
with <10,000 activity counts. Low intensity activity (slow walking) included 10-minute bouts
with 10,000-30,000 counts. Moderate intensity activity (slow to fast walking) included epochs
with 30,000-50,000 counts, and Vigorous intensity movement (fast walking to running) included
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10-minute bouts with >50,000 counts. The number of minutes subjects engaged in each intensity
level of activity, vigorous, moderate, low, and sedentary, was used to differentiate among
subjects.
Dietary and Supplemental Intake of Calcium and Vitamin D
In the present study, subjects completed the Block food frequency questionnaire
(Nutrition Quest, Berkeley, CA), originally developed by the National Cancer Institute. The
instrument was employed in the present study to assess dietary calcium and supplemental
calcium intake. Similarly, vitamin D derived from foods and beverages, along with supplemental
vitamin D, were measured using the Block questionnaire.
The Block food frequency questionnaire is eight pages in length and includes questions
about serving size and serving frequency for more than 100 different foods. Additionally, the
instrument includes questions about dietary supplement use. A full-page illustration, showing
various common portion sizes, was given to each subject so that portion sizes could be more
easily interpreted. The questionnaire relies on national dietary data, including data from the
National Health and Nutrition Examination Survey (NHANES), and it is considered to be a valid
and reliable instrument for assessing dietary intake (60, 61).
Menopause and Bone Enhancing Prescription Drugs
To assess other possible confounding variables in the study, each subject completed a
questionnaire about menopause status and bone enhancing prescription drug use. Six questions
were asked regarding menopause status specifically ascertaining symptoms of menopause,
characteristics and duration of the menstrual cycle, time since the last menstrual cycle, and other
related factors. According to their answers, subjects were labeled as premenopausal,
perimenopausal, postmenopausal, or hysterectomy. Blood test results from a sample of 198
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women in the study were used to validate the questionnaire. The follicle-stimulating hormone
blood test results, which are indicative of ovarian function, were highly correlated with
menopause status (F=52.3, r2=0.45, P<0.0001)(62). The questionnaire also included questions
regarding any physician-prescribed bone enhancing drugs used to enhance bone mineral density
during the previous 10 years from that point in time.
Data Analysis
A power analysis indicated that 246 subjects were needed to detect a small effect size
with 0.80 power with subjects divided into three groups and alpha set at 0.05. Using 262
participants, statistical power was 0.90 to detect a small linear association between body mass
and BMD with alpha set at 0.05.
To differentiate among levels of hip bone mineral density (BMD), subjects were divided
into quartiles and the two middle categories were collapsed to form three BMD categories (Low,
Moderate, High). Mean levels of total body mass (TBM), fat-free mass (FFM), fat-free mass
minus bone mineral content (FFM-BMC), and fat mass (FM) were compared across the three
BMD categories, with and without control of the potentially confounding variables, which
included: age, height, total and intensity of physical activity, dietary and supplemental intake of
calcium and vitamin D, menopause status, and the use of bone enhancing prescription drugs.
Means were adjusted for differences in the potential confounding variables and compared across
the BMD groups using partial correlation and least squared means. Additionally, multiple
regression analysis was employed to estimate BMD using TBM, FFM, FFM-BMC, and FM,
considered separately as predictors. Potential confounders were controlled statistically and
regression coefficients (b) were adjusted according to the influence of the covariates, considered
individually and collectively. Statistical significance was determined with alpha set at the 0.05
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level. Data analysis for this study was conducted using SAS, version 9.3 (SAS Institute, Inc.,
Cary, NC, 2010).

RESULTS
Descriptive characteristics of the 262 females included in the analyses are given in Table
1. Additional findings indicate that 191 of the women (73%) were premenopausal, 34 (13%)
were perimenopausal, 15 (6%) were postmenopausal, and 22 (8%) had a hysterectomy. A total of
22 (8%) of the subjects reported taking physician-prescribed bone enhancing drugs in the
previous 10 years. Mean total body mass (TBM), fat-free mass (FFM), and fat mass (FM) were
65.9±10.8 kg, 44.1±5.2 kg, and 21.8±7.7 kg, respectively. Mean bone mineral density (BMD)
was 0.934 ± 0.112 g/cm2.
As shown in Table 2, mean differences in hip BMD across low, moderate, and high FFM
categories indicated a strong and significant relationship (F=24.5, P<0.0001). When using the
pooled standard deviation, there was a large effect size of 1.2 when comparing hip BMD of
women with low FFM and high FFM. After controlling for each potentially confounding variable
individually, the relationship remained significant in all instances. Potentially confounding
variables considered collectively in two separate models were also controlled and did not change
the relationship.
In Table 3, the relationship between hip BMD across low, moderate, and high FM
categories is displayed. The results indicated that this relationship was both strong and
significant as well (F=9.9, P<0.0001). Controlling for the potentially confounding variables,
including age, height, calcium and vitamin D intake, volume and intensity of physical activity,
menopause status, and prescription drug use for bones, did not change the significance of the
relationship. However, the relationship between hip BMD across the three FM categories was
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not significant after controlling for FFM (F=2.1, P=0.1213) or Full Model 1, which included
FFM (F=1.0, P=0.3692). After adjusting for differences in TBM, the relationship remained
statistically significant, albeit not as strong as the other associations (F=3.6, P=0.0287).
According to Table 4, mean differences in hip BMD across low, moderate, and high
TBM categories revealed a significant and dose-response association, with no potential
confounders controlled statistically (F=21.5, P<0.0001), similar to the other relationships shown
in Tables 2 and 3. After controlling for each of the potentially confounding variables separately,
only one of the associations became non-significant. Specifically, adjusting for differences in
FFM weakened the association by 94% (F=1.3, P=0.2693). Similarly, adjusting for differences in
the Full Model 1 weakened the hip BMD and TBM association to the point of non-significance,
because the model included FFM (F=0.3, P=0.7188). However, adjusting for all the potential
confounders except FFM left the association strong and dose-response (F=15.3, P<0.0001).
Additional findings in Table 5 show the relationships between hip BMD and FFM, FFMBMC, FM, or TBM, with and without control of potentially confounding variables. Analyses
performed using regression coefficients (b) reflect differences in hip BMD for each 1 kg
difference in the body mass variables treated separately (FFM, FFM-BMC, FM, and TBM).
Without control of the potentially confounding variables, a highly significant relationship was
unveiled between BMD and each body mass variable (P<0.0001). For every 1 kg difference in
FFM, FFM-BMC, FM, or TBM, BMD differed by 0.0100, 0.0101, 0.0036, and 0.0042 g/cm2,
respectively. After controlling for each of the potentially confounding variables, the relationship
between BMD and body mass (FFM, FFM-BMC, FM, and TBM) remained highly significant in
almost every instance (P<0.0001). However, after controlling for FFM, the relationship between
BMD and FM, and BMD and TBM, were not statistically significant (P=0.1316). Also, after
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controlling for every variable in the Full Model, which included either FFM or FM depending on
the association evaluated, the relationships between BMD and FM, and BMD and TBM, were
not significant (P=0.4109).

DISCUSSION
The key finding of the present study was that fat-free mass (FFM) is a strong and robust
predictor of hip BMD in middle-aged women, and this association is not modified or influenced
by any of a large number of potentially confounding factors, considered individually or in
combination. Evidently, women with low FFM tend to have low hip BMD, and it does not matter
whether or not they are older or younger, taller or shorter, premenopausal or postmenopausal,
physically active or inactive, or whether they consume significant levels of calcium and vitamin
D or not. In short, it appears that FFM is the driving factor that predicts hip BMD, independent
of demographics, lifestyle, and other factors.
Results indicate that total body mass (TBM) and fat mass (FM) were also strong
predictors of hip BMD in the present sample. Similar to the FFM relationship, the TBM and FM
connections with hip BMD do not appear to be strengthened or weakened by age, height,
menopause status, physical activity, diet, prescription drug use, or other factors. However, the
associations between hip BMD, TBM and FM seem to be eliminated when differences in FFM
are controlled. Hence, when it comes to hip BMD, FFM seems to be the key.
Because the present study employed a cross-sectional design, cause-and-effect cannot be
inferred. However, if a causal relationship is assumed, then women with low FFM are at risk of
developing low hip BMD, and from the results of this study, it appears that there is little that
women can do to alter this unhealthy connection, other than increase their body mass,
particularly their FFM. Increasing FM may also help to increase hip BMD, although probably
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not as much as FFM, but this would be ill-advised because of the many health problems
associated with obesity.
As presented in the literature, there are a number of studies that have examined the
relationship between FFM and BMD. This study supports the hypothesis that BMD is largely a
function of individual FFM (12-14), as well as TBM (8, 9) and FM (15-17). However, to date,
very few if any investigations have examined the extent to which the body mass and BMD
relationship is modified by potential confounding factors.
The present study had many strengths. First, several high quality measurement methods were
employed. Calcium and vitamin D intake were assessed using a validated food frequency
questionnaire. Additionally, physical activity was measured objectively using accelerometry,
whereas hip BMD and body fat percentage were evaluated using dual energy x-ray
absorptiometry (DXA). Furthermore, many potential confounding variables were studied
individually and collectively to determine the extent to which the body mass and hip BMD
relationship is influenced by these factors, which has never been evaluated in the past. Lastly,
statistical power was excellent in the present investigation, increasing the probability of detecting
significant relationships when present.
The current investigation was not without weaknesses, however. The cross-sectional design
prevented cause-and-effect conclusions. Also, participants were somewhat homogeneous,
potentially limiting the generalizability of the results. Lastly, although physical activity was
measured objectively, participation in strength training was not assessed, which could have
influenced participant FFM and may have modified the relationship between FFM and BMD.
More research is needed in this area. Although difficult, lengthy randomized controlled
trials or prospective cohort investigations could help to decipher the extent to which the strong
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relationship between FFM and hip BMD can be modified by diet, exercise, or other factors.
Additional research would be valuable focusing on the amount of FFM women need to prevent
risk of low BMD at the hip. The present study indicates that the association is linear and there is
no threshold effect. Lastly, examination of the relationship between FFM and BMD and the
effect of strength training to build FFM in women without increasing FM could also be
enlightening and lead to additional insights regarding improvement of hip BMD.
In conclusion, body mass, particularly FFM, seems to contribute significantly to hip
BMD in middle-aged women. Those with high levels of FFM tend to have high levels of BMD,
potentially reducing risk of osteopenia and osteoporosis. Conversely, women with low levels of
body mass, particularly FFM, tend to have low levels of hip BMD, possibly increasing risk of
osteopenia and osteoporosis. It appears that the body mass and BMD relationship is not
influenced in any way by a number of factors, making it challenging for women with low FFM
to avoid risk of low BMD.
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Table 1 Descriptive information for all participants (n=262)

75th
percentile

Variables

MEAN

SD

Age (yrs)

41.6

3.0

36.0

39.0

42.0

44.0

47.0

166.4

6.9

143.5

162.3

166.1

170.4

189.2

Height (cm)
BMD (g/cm2)

0.934

0.112

MIN

25th
percentile

0.659

0.855

MED

0.932

1.010

MAX

1.354

Total Body Mass (kg)

65.9

10.8

42.7

58.2

64.6

73.0

96.4

Fat-Free Mass (kg)

44.1

5.2

32.4

40.3

44.2

47.4

63.5

Fat Mass (kg)

21.8

7.7

7.0

15.5

21.1

27.5

45.9

FFM-BMC

42.4

5.0

301.0

38.8

42.4

45.5

61.1

Dietary calcium (mg)

839.2

372.4

100.1

554.1

782.1

1072.8

2051.5

Suppl. calcium (mg)

326.7

419.0

0

0

92.9

714.5

1130.0

Total calcium (mg)

1165.9

553.0

230.0

709.1

1075.9

1526.4

3074.8

Dietary vitamin D (IU)

147.8

122.0

0.430

549.8

102.6

203.9

587.1

Suppl. vitamin D (IU)

141.3

165.7

0

0

0

285.8

400.0

Total vitamin D (IU)

289.1

218.8

0.430

93.7

255.4

448.6

987.1

Total PA (counts)

26.6

9.5

8.3

19.6

25.0

31.4

66.4

Vigorous PA (min)

32.7

64.2

0

0

0

40.0

420.0

Moderate PA (min)

40.3

48.8

0

0

20.0

60.0

250.0

MVPA (min)

73.1

89.1

0

0

40.0

110.0

470.0

Note: Total PA counts were divided by 100,000 to yield a manageable data set. Vigorous PA, Moderate PA, and MVPA
indicate the number of minutes per week engaged in the specific intensity of activity.
SD: standard deviation, MIN: minimum, MED: median, MAX: maximum, BMD: bone mineral density, FFM-BMC: fatfree mass minus bone mineral content, PA: physical activity, MVPA: moderate and vigorous physical activity
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Table 2 Mean differences in hip BMD across three categories of fat-free mass, without and with the
effect of potential confounders
Fat-Free Mass Category
Low FFM
n=66
Outcome: Hip BMD

Moderate
FFM
n=130

High FFM
n=66

Mean

SD

Mean

SD

Mean

SD

F

P

None

0.871a

0.089

0.933b

0.096

0.997c

0.128

24.5

<0.0001

Age (yrs)

0.871a

0.933b

0.997c

24.3

<0.0001

Height (cm)

0.863a

0.934b

1.004c

19.9

<0.0001

Fat Mass (kg)

0.877a

0.934b

0.990c

17.5

<0.0001

Total Body Mass (kg)

0.896a

0.934b

0.970c

4.8

< 0.0091

Dietary calcium (mg)

0.873a

0.933b

0.996c

23.0

<0.0001

Suppl. calcium (mg)

0.871a

0.933b

0.997c

24.5

<0.0001

Total calcium (mg)

0.871a

0.933b

0.997c

24.2

<0.0001

Dietary vitamin D (IU)

0.872a

0.932b

0.997c

24.4

<0.0001

Suppl. vitamin D (IU)

0.872a

0.933b

0.997c

24.3

<0.0001

Total vitamin D (IU)

0.872a

0.932b

0.997c

24.3

<0.0001

Total PA (counts)

0.869a

0.934b

0.998c

25.1

<0.0001

Vigorous PA (min)

0.870a

0.933b

0.997c

24.8

<0.0001

Moderate PA (min)

0.871a

0.933b

0.997c

24.2

<0.0001

MVPA (min)

0.870a

0.933b

0.998c

24.7

<0.0001

Bone drugs (yes/no)

0.839a

0.891b

0.959c

23.8

<0.0001

Menopause status

0.876a

0.939b

1.003c

24.3

<0.0001

Full Model 1

0.879a

0.935b

1.004c

14.3

<0.0001

Full Model 2

0.875a

0.937b

1.013c

19.5

<0.0001

Variable controlled

Note: Means on the same row with the same superscript letter are not significantly different.
BMD: bone mineral density, FFM: fat-free mass, PA: physical activity, MVPA: moderate and vigorous physical activity
Low FFM: ≤40.27 kg, Moderate FFM: >40.27 kg and ≤47.44 kg, High FFM: >47.44 kg
Full Model 1 includes statistical control of the following variables: age, height, menopause status, bone drug use, total
vitamin D intake, total calcium intake, time spent in moderate and vigorous physical activity, and fat mass.
Full Model 2 includes all of the covariates of Full Model 1, except fat mass.
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Table 3 Mean differences in hip BMD across three categories of fat mass, without and with the effect of
potential confounders
Fat Mass Category
Low FM
n=66
Outcome: Hip BMD

Moderate FM
n=130

High FM
n=66

Mean

SD

Mean

SD

Mean

SD

F

P

None

0.910a

0.115

0.920a

0.102

0.985b

0.113

9.9

<0.0001

Age (yrs)

0.908a

0.920a

0.985b

10.1

<0.0001

Height (cm)

0.913a

0.920a

0.980b

8.3 < 0.0003

Fat-Free Mass (kg)

0.925

0.926

0.957

2.1 < 0.1213

Total Body Mass (kg)

0.974a

0.928b

0.904b

3.6 < 0.0287

Dietary calcium (mg)

0.909a

0.921a

0.983b

9.4

<0.0001

Suppl. calcium (mg)

0.910a

0.920a

0.984b

9.6

<0.0001

Total calcium (mg)

0.909a

0.920a

0.985b

10.0

<0.0001

Dietary vitamin D (IU)

0.908a

0.921a

0.984b

10.1

<0.0001

Suppl. vitamin D (IU)

0.910a

0.920a

0.985b

9.9

<0.0001

Total vitamin D (IU)

0.908a

0.920a

0.985b

10.1

<0.0001

Total PA (counts)

0.908a

0.920a

0.986b

10.1

<0.0001

Vigorous PA (min)

0.907a

0.920a

0.986b

10.2

<0.0001

Moderate PA (min)

0.909a

0.920a

0.985b

10.1

<0.0001

MVPA (min)

0.907a

0.920a

0.986b

10.4

<0.0001

Bone drugs (yes/no)

0.874a

0.881a

0.985b

Menopause status

0.910a

0.918a

0.984b

Full Model 1

0.934

0.934

0.955

1.0 < 0.3692

Full Model 2

0.912a

0.924a

0.980b

7.7 < 0.0006

Variable controlled

8.9 < 0.0002
10.0

<0.0001

Note: Means on the same row with the same superscript letter are not significantly different.
BMD: bone mineral density, FM: fat mass, PA: physical activity, MVPA: moderate and vigorous physical activity
Low FM: ≤15.52 kg, Moderate FM: >15.52 kg and ≤27.45 kg, High FM: >27.45 kg
Full Model 1 includes statistical control of the following variables: age, height, menopause status, bone drug use, total
vitamin D intake, total calcium intake, time spent in moderate and vigorous physical activity, and fat-free mass.
Full Model 2 includes all of the covariates of Full Model 1, except fat-free mass.
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Table 4 Mean differences in hip BMD across three categories of total body mass, without and with the
effect of potential confounders
Total Body Mass Category
Low TBM
n=66
Outcome: Hip BMD

Moderate
TBM
n=130
Mean
SD

Mean

SD

F

P

0.932b

0.995c

0.112

21.5

<0.0001

High TBM
n=66

Mean

SD

None

0.876a

0.085

Age (yrs)

0.875a

0.933b

0.994c

21.8

<0.0001

Height (cm)

0.879a

0.932b

0.992c

16.6

<0.0001

Fat Mass (kg)

0.857a

0.929b

1.018c

13.7

<0.0001

Fat-Free Mass (kg)

0.916

0.932

0.953

Dietary calcium (mg)

0.873a

0.933b

0.996c

23.0

<0.0001

Suppl. calcium (mg)

0.876a

0.932b

0.994c

21.0

<0.0001

Total calcium (mg)

0.875a

0.932b

0.994c

21.5

<0.0001

Dietary vitamin D (IU)

0.877a

0.931b

0.995c

21.2

<0.0001

Suppl. vitamin D (IU)

0.874a

0.933b

0.995c

22.0

<0.0001

Total vitamin D (IU)

0.874a

0.933b

0.995c

22.1

<0.0001

Total PA (counts)

0.875a

0.932b

0.995c

21.5

<0.0001

Vigorous PA (min)

0.874a

0.933b

0.996c

22.1

<0.0001

Moderate PA (min)

0.876a

0.932b

0.995c

21.3

<0.0001

MVPA (min)

0.875a

0.932b

0.995c

22.0

<0.0001

Bone drugs (yes/no)

0.847a

0.896b

0.956c

19.0

<0.0001

Menopause status

0.871a

0.928b

0.991c

21.4

<0.0001

Full Model 1

0.930

0.938

0.950

Full Model 2

0.879a

0.932b

0.989c

Variable controlled
0.109

1.3 < 0.2693

0.3 < 0.7188
15.3

<0.0001

Note: Means on the same row with the same superscript letter are not significantly different.
BMD: bone mineral density, TBM: total body mass, PA: physical activity, MVPA: moderate and vigorous physical
activity
Low TBM: ≤58.23 kg, Moderate TBM: >58.23 kg and ≤73.00 kg, High TBM: >73.00 kg
Full Model 1 includes statistical control of the following variables: age, height, menopause status, bone drug use, total
vitamin D intake, total calcium intake, time spent in moderate and vigorous physical activity, and fat-free mass.
Full Model 2 includes all of the covariates of Full Model 1, except fat-free mass.
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Table 5 Relationship between hip BMD, FFM, FFM-BMC, Fat Mass, and Total Body Mass, without and
with control of potential confounders
Body Mass Category
n=262
FFM
Criterion: Hip BMD

b

FFM-BMC
p

b

p

FM
b

TBM
p

b

p

Variable controlled
None

0.0100 <0.0001

0.0101 <0.0001

0.0036 <0.0001

0.0042 <0.0001

Age (yrs)

0.0100 <0.0001

0.0100 <0.0001

0.0037 <0.0001

0.0042 <0.0001

Height (cm)

0.0127 <0.0001

0.0125 <0.0001

0.0032 < 0.0004 0.0042 <0.0001

Fat Mass (kg)

0.0103 <0.0001

0.0093 <0.0001

Fat-Free Mass (kg)

N/A

N/A

N/A

N/A

N/A

N/A

0.0093 <0.0001

0.0013 < 0.1316 0.0013 < 0.1316

Dietary calcium (mg)

0.0100 <0.0001

0.0110 <0.0001

0.0035 <0.0001

0.0041 <0.0001

Suppl. calcium (mg)

0.0100 <0.0001

0.0101 <0.0001

0.0036 <0.0001

0.0042 <0.0001

Dietary vitamin D (IU)

0.0100 <0.0001

0.0110 <0.0001

0.0036 <0.0001

0.0042 <0.0001

Suppl. vitamin D (IU)

0.0100 <0.0001

0.0101 <0.0001

0.0036 <0.0001

0.0042 <0.0001

Total PA (counts)

0.0103 <0.0001

0.0103 <0.0001

0.0038 <0.0001

0.0042 <0.0001

Vigorous PA (min)

0.0101 <0.0001

0.0102 <0.0001

0.0039 <0.0001

0.0043 <0.0001

Moderate PA (min)

0.0101 <0.0001

0.0101 <0.0001

0.0036 <0.0001

0.0042 <0.0001

MVPA (min)

0.0102 <0.0001

0.0102 <0.0001

0.0038 <0.0001

0.0042 <0.0001

Bone drugs (yes/no)

0.0096 <0.0001

0.0107 <0.0001

0.0032 < 0.0003 0.0039 <0.0001

Full Model

0.0120 <0.0001

0.0116 <0.0001

0.0007 < 0.4109 0.0007 < 0.4109

Note: b=regression coefficient. Values in the columns showing regression coefficients (b) reflect differences in BMD for
each 1 kg difference in the body mass category.
BMD: bone mineral density, FFM: fat-free mass, FFM-BMC: fat-free mass minus bone mineral content, FM: fat mass,
TBM: total body mass, PA: physical activity, MVPA: moderate and vigorous physical activity
Full Model included the following covariates: age, height, total vitamin D intake, total calcium intake, time in moderate
and vigorous physical activity, use of bone drugs, and either fat-free mass or fat mass, depending on the criterion variable.

